Abiopharma

🔍 Laufman James (Executive)

Company: Credo Technology Group Holding Ltd (CRDO)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Sold 7,379 shares of Ordinary Shares at $245.97 per share (Direct)
  Date: 2026-08-19 | Code: F | equity_swap_involved: 0 | shares_owned_after: 174,223.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs.
• F2: The number of securities reported includes the acquisition on June 30, 2026 of 372 shares of the Issuer's common stock pursuant to the Issuer's employee stock purchase plan for the purchase period of January 1, 2026 through July 1, 2026. In accordance with the Issuer's employee stock purchase plan, these shares were purchased based on 85% of the grant date fair market value of a share on December 31, 2024.